Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

As the summer of 2012 wears on, an outpouring of negative clinical trial news for high-profile new drug candidates has made the season more a time of doldrums than of fun in the sun for big pharma.


Related Content

Lilly Pulls The Plug On Next-Gen Antipsychotic
Beyond Bapi: Alzheimer’s Pipeline Runs Deep
Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?
Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
FDA and the R&D Crisis: Time to Stop the Blame Game
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts